Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards

April 21, 2009

SINGAPORE, April 21 /PRNewswire-Asia/ — Moleac has been named the
Singapore Entrepreneurial Company of the Year, by Frost & Sullivan. This award
recognizes companies that have pushed the boundaries of excellence in the
healthcare industry and acknowledges Moleac’s outstanding performance in 2008.
Mr David Picard, CEO of Moleac, received the 2009 Frost & Sullivan Asia
Pacific Excellence in Healthcare Award for Singapore Entrepreneurial Company
of the Year at the awards ceremony held this evening. The ceremony was
attended by over 150 industry leaders from the region’s healthcare sector.

Frost & Sullivan followed a rigorous measurement-based methodology to
select Moleac as the recipient. Its independent panel of judges included
senior members across different offices at Frost & Sullivan. The judging panel
looked at market performance indicators, including revenue growth, market
share, demonstrated leadership, geographical expansion and business/marketing

Sohini Mitra, research manager, Asia Pacific Healthcare practice at Frost
& Sullivan, said, “Moleac has identified a need gap in the stroke recovery
process and has adopted an innovative approach to address this void. NeuroAid,
the company’s flagship product, is derived from Traditional Chinese Medicine
(TCM) and helps patients recover functional skills in the post stroke
rehabilitation process — addressing a gap that has not been filled by western

She further adds, “The approach of taking from TCM to fill a gap in
western treatment options is not only innovative but is also highly efficient
in terms of product commercialization. As the efficacy of TCM is proven, the
company has been able to develop NeuroAid with relatively low investments and
commercialize it in a relatively short period span of less than 5 years. In
the short period since its launch, NeuroAid has become a product with global
reach. It has witnessed considerable geographic expansion outside its home
country. The success of the product is evident in the dramatic revenue growth
between 2006 and 2008 and the aggressive multi-million dollar targets that the
company has set for itself in 2009.”

David Picard, CEO of Moleac, said, “I am delighted to receive this award
from Frost & Sullivan, which is a confirmation of our early successes. Having
launched NeuroAid in 2006, we have been focusing our efforts on making
NeuroAid available to stroke sufferers around the world. NeuroAid is the first
medicine to support stroke recovery, and this is a huge unmet need for
patients. In 2008, Moleac shipped 3,000 months of treatment of NeuroAid,
bringing its benefits to many stroke patients around the world. I am very
pleased that we were able to do our part in helping them in their recovery.”

He continued to add, “I would like to thank all those who have supported
Moleac over the past few years. This includes our academic partners, who have
shown interest in our approach, enabling its clinical development, our
investors who have trusted us, and of course my colleagues who have made this
venture a success. Without this support, receiving this award would not have
been possible.”

    Moleac's achievements in 2008 include:
    -- Closing a Series A round of funding at US$ 3.5 million
    -- Launching NeuroAid in new territories, such as Philippines, Malaysia,
       Lebanon and Jordan. NeuroAid is now listed in 9 countries
    -- Incorporating a European subsidiary in Paris, to ensure NeuroAid
       becomes available to patients in Europe rapidly, first through a Named
       Patient Program.
    -- Tripling sales volume of NeuroAid, to reach over US$900,000 (for 2008)

NeuroAid is a natural medicine originating in Traditional Chinese
Medicine. Clinical trials have shown that patients taking NeuroAid within six
months from a stroke have 2.4 more chances to achieve a fuller recovery, as
published recently in Stroke (March 2009). Moleac is currently supporting the
international CHIMES clinical trial, to demonstrate the efficacy of NeuroAid
during the acute stage of a stroke. This will be the largest clinical trial on
stroke recovery, which aims to recruit 1,100 stroke patients. Such studies
will reinforce the evidence base for strokologists and patients on starting
NeuroAid as soon as possible after a stroke.

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates
itself in finding and developing new medicines for the unmet needs of patients

About NeuroAid

NeuroAid is a stroke treatment to help stroke patients achieve faster and
better recovery. NeuroAid is derived from 14 components, carefully selected
for their efficacy and absence of side effects. It currently reaches out to
patients in over 25 countries.

    Contact details:

     Chan Yiu Lin
     Greener Grass Communications
     Mobile: +65-9-7655897
     Email:  yiulin@greenergrass.com.sg


Source: newswire

comments powered by Disqus